Brief: Anixa Biosciences Enters Letter of Intent with VERDI Solutions to Develop Artificial Intelligence-Guided Personalized and Off-the-Shelf Cancer Vaccines
25/03/2025 12:24
March 25 (Reuters) - Anixa Biosciences Inc ANIX.O: ANIXA BIOSCIENCES ENTERS LETTER OF INTENT WITH VERDI SOLUTIONS TO DEVELOP ARTIFICIAL INTELLIGENCE-GUIDED PERSONALIZED AND OFF-THE-SHELF CANCER VACCINES Source text: ID:nPnbwh3cRa Further company coverage: ANIX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Anixa Biosciences
See all newsBrief: Anixa Biosciences Announces First Case Of Stable Disease For Three Months In Ovarian Cancer Car-T Clinical Trial
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
Anixa Biosciences Inc reports results for the quarter ended July 31 - Earnings Summary
Anixa Biosciences Inc expected to post a loss of 9 cents a share - Earnings Preview
Factbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine